Protocol Ledger

NCT05743244 · Phase II · ACTIVE NOT RECRUITING

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Interventional Phase II clinical trial protocol NCT05743244 sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-19 Enrollment: 78 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05743244
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)78 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05743244
Protocol FieldVerified Registry Value
NCT IdentifierNCT05743244
Consolidated Lead SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment78 participants (ESTIMATED)
Registered Start Date2023-10-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI